Clinical Trials
Rilvegostomig + Chemo for 1st line treatment of patients with metastatic Non-squamous NSCLC with PDL1 expression
Disease Type: Lung
A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville